
Arrowhead Pharmaceuticals Finalizes Global Licensing and Collaboration Deal with Novartis
Arrowhead Pharmaceuticals Announces Completion of Global Licensing and Collaboration Agreement with Novartis Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), a leading biopharmaceutical company focused on developing innovative RNA interference (RNAi) therapeutics, announced today that its previously disclosed global licensing and collaboration agreement…











